Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts

References

• Aaseth J, Alexander J, Bjørklund G, Hestad K, Dusek P, Roos PM, Alehagen U. 2016. Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation. Biometals. 29:827–839.
   PubMed Web of Science ®Google Scholar
• Ablain J, Leiva M, Peres L, Fonsart J, Anthony E, de Thé H. 2013. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies. J Exp Med. 210:647–653.
   PubMed Web of Science ®Google Scholar
• Ablain J, Rice K, Soilihi H, De Reynies A, Minucci S, de Thé H. 2014. Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 20:167–174.
   PubMed Web of Science ®Google Scholar
• Adès L, Guerci A, Raffoux E, Sanz M, Chevallier P, Lapusan S, Recher C, Thomas X, Rayon C, Castaigne S, for the European APL Group 2010. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 115:1690–1696.
   PubMed Web of Science ®Google Scholar
• Agusa T, Fujihara J, Takeshita H, Iwata H. 2011. Individual variations in inorganic arsenic metabolism associated with AS3MT genetic polymorphisms. Int J Mol Sci. 12:2351–2382.
   PubMed Web of Science ®Google Scholar
• Ajees AA, Marapakala K, Packianathan C, Sankaran B, Rosen BP. 2012. Structure of an As(III) S-adenosylmethionine methyltransferase: insights into the mechanism of arsenic biotransformation. Biochemistry. 51:5476–5485.
   PubMed Web of Science ®Google Scholar
• Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. 2001. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med. 7:680–686.
   PubMed Web of Science ®Google Scholar
• Aposhian HV. 1997. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu Rev Pharmacol Toxicol. 37:397–419.
   PubMed Web of Science ®Google Scholar
• Au WY, Tam S, Fong BM, Kwong YL. 2008. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 112:3587–3590.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Mandelli F, Petti MC, Vegna ML, Spadea A, Liso V, Specchia G, Bernasconi C, Alessandrino EP, Piatti C. 1990. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol. 44:257–260.
   PubMed Web of Science ®Google Scholar
• Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. 1973. Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood. 41:489–496.
   PubMed Web of Science ®Google Scholar
• Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ. 2000. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 14:262–270.
   PubMed Web of Science ®Google Scholar
• Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. 1990. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood. 76:1704–1709.
   PubMed Web of Science ®Google Scholar
• Challenger F. 1945. Biological methylation. Chem Rev. 36:315–361.
   Web of Science ®Google Scholar
• Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM. 1997. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 89:3345–3353.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Waxman S. 2003. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 63:1853–1859.
   PubMed Web of Science ®Google Scholar
• Cullen WR, Reimer KJ. 1989. Arsenic speciation in the environment. Chem Rev. 89:713–764.
   Web of Science ®Google Scholar
• Cullen WR, McBride BC, Reglinski J. 1984a. The reaction of methylarsenicals with thiols: some biological implications. J Inorg Biochem. 21 :179–193.
   Web of Science ®Google Scholar
• Cullen WR, McBride BC, Reglinski J. 1984b. The reduction of trimethylarsine oxide to trimethylarsine by thiols: a mechanistic model for the biological reduction of arsenicals. J Inorg Biochem. 21:45–60.
   Web of Science ®Google Scholar
• Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. 1989. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 73:1116–1122.
   PubMed Web of Science ®Google Scholar
• de Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X, Mediavilla JD, Recher C, Ades L, Quesnel B. 2006. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 20:35–41.
   PubMed Web of Science ®Google Scholar
• De Loma J, Skröder H, Raqib R, Vahter M, Broberg K. 2018. Arsenite methyltransferase (AS3MT) polymorphisms and arsenic methylation in children in rural Bangladesh. Toxicol Appl Pharmacol. 357:80–87.
   PubMed Web of Science ®Google Scholar
• de Thé H, Pandolfi PP, Chen Z. 2017. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. 32:552–560.
   PubMed Web of Science ®Google Scholar
• Desaint S, Luriau S, Aude JC, Rousselet G, Toledano MB. 2004. Mammalian antioxidant defenses are not inducible by H2O2. J Biol Chem. 279:31157–31163.
   PubMed Web of Science ®Google Scholar
• Dewaele M, Maes H, Agostinis P. 2010. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy. 6:838–854.
   PubMed Web of Science ®Google Scholar
• Dheeman DS, Packianathan C, Pillai JK, Rosen BP. 2014. Pathway of human AS3MT arsenic methylation. Chem Res Toxicol. 27:1979–1989.
   PubMed Web of Science ®Google Scholar
• Drobna Z, Naranmandura H, Kubachka KM, Edwards BC, Herbin-Davis K, Styblo M, Le XC, Creed JT, Maeda N, Hughes MF. 2009. Disruption of the arsenic (+ 3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem Res Toxicol. 22:1713–1720.
   PubMed Web of Science ®Google Scholar
• Drobná Z, Waters SB, Devesa V, Harmon AW, Thomas DJ, Stýblo M. 2005. Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+ 3 oxidation state)-methyltransferase. Toxicol Appl Pharmacol. 207:147–159.
   PubMed Web of Science ®Google Scholar
• Fan XY, Liu YJ, Cai YM, Wang AD, Xia YZ, Hu YJ, Jiang FL, Liu Y. 2019. A mitochondria-targeted organic arsenical accelerates mitochondrial metabolic disorder and function injury. Bioorg Med Chem. 27:760–768.
   PubMed Web of Science ®Google Scholar
• Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y. 2007. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol. 59:485–493.
   PubMed Web of Science ®Google Scholar
• Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S. 2006. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biol Pharm Bull. 29:1022–1027.
   PubMed Web of Science ®Google Scholar
• Gambino V, De Michele G, Venezia O, Migliaccio P, Dall'Olio V, Bernard L, Minardi SP, Della Fazia MA, Bartoli D, Servillo G. 2013. Oxidative stress activates a specific p53 transcriptional response that regulates cellular senescence and aging. Aging Cell. 12:435–445.
   PubMed Web of Science ®Google Scholar
• Gao C, Hu S, Guo M, Hai X, Zhou J. 2018. Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Cancer Chemother Pharmacol. 82:229–236.
   PubMed Web of Science ®Google Scholar
• Goldman SL, Hassan C, Khunte M, Soldatenko A, Jong Y, Afshinnekoo E, Mason CE. 2019. Epigenetic modifications in acute myeloid leukemia: prognosis, treatment, and heterogeneity. Front Genet. 10:133.
   PubMed Web of Science ®Google Scholar
• Guo M, Li J, Fan S, Liu W, Wang B, Gao C, Zhou J, Hai X. 2019a. Speciation analysis of arsenic in urine samples from APL patients treated with single agent As2O3 by HPLC-HG-AFS. J Pharm Biomed Anal. 171:212–217.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang B, Liu S, Wang W, Gao C, Hu S, Fan S, Hai X, Zhou J. 2019b. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Expert Rev Clin Pharmacol. 12:371–378.
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Kobayashi Y, Cui X, Hirano S. 2005. A new metabolic pathway of arsenite: arsenic–glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch Toxicol. 79:183–191.
   PubMed Web of Science ®Google Scholar
• Head DR, Kopecky KJ, Willman C, Appelbaum FR. 1994. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience. Leukemia. 8:S38–S41.
   PubMed Web of Science ®Google Scholar
• Hosein PJ, Craig MD, Tallman MS, Boccia RV, Hamilton BL, Lewis JJ, Lossos IS. 2012. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma. Am J Hematol. 87:111–114.
   PubMed Web of Science ®Google Scholar
• Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. 2010. CNS relapse in acute promyeloctyic leukemia. J Clin Oncol. 28:E409–E411.
   PubMed Web of Science ®Google Scholar
• Huang M, Douillet C, Stýblo M. 2019. Arsenite and its trivalent methylated metabolites inhibit glucose-stimulated calcium influx and insulin secretion in murine pancreatic islets. Arch Toxicol. 93:2525–2533.
   PubMed Web of Science ®Google Scholar
• Huang MC, Douillet C, Su M, Zhou K, Wu T, Chen W, Galanko JA, Drobná Z, Saunders RJ, Martin E. 2017. Metabolomic profiles of arsenic (+3 oxidation state) methyltransferase knockout mice: effect of sex and arsenic exposure. Arch Toxicol. 91:189–202.
   PubMed Web of Science ®Google Scholar
• Hussain L, Maimaitiyiming Y, Islam K, Naranmandura H. 2019. Acute promyelocytic leukemia and variant fusion proteins: PLZF-RARα fusion protein at a glance. Semin Oncol. 46:133–144.
   PubMed Web of Science ®Google Scholar
• Isakson P, Bjørås M, Bøe SO, Simonsen A. 2010. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood. 116:2324–2331.
   PubMed Web of Science ®Google Scholar
• Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L, Berthier C, Soilihi H, Raught B. 2010. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 18:88–98.
   PubMed Web of Science ®Google Scholar
• Khaleghian A, Ghaffari SH, Ahmadian S, Alimoghaddam K, Ghavamzadeh A. 2014. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells. J Cell Biochem. 115:1729–1739.
   PubMed Web of Science ®Google Scholar
• Kim GH, Kim JE, Rhie SJ, Yoon S. 2015. The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol. 24:325–340.
   PubMed Web of Science ®Google Scholar
• Kitchin KT, Wallace K. 2008. The role of protein binding of trivalent arsenicals in arsenic carcinogenesis and toxicity. J Inorg Biochem. 102:532–539.
   PubMed Web of Science ®Google Scholar
• Kligerman AD, Doerr CL, Tennant AH, Harrington-Brock K, Allen JW, Winkfield E, Poorman-Allen P, Kundu B, Funasaka K, Roop BC. 2003. Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ Mol Mutagen. 42:192–205.
   PubMed Web of Science ®Google Scholar
• Lee J, Levin DE. 2019. Methylated metabolite of arsenite blocks glycerol production in yeast by inhibition of glycerol-3-phosphate dehydrogenase. Mol Biol Cell. 30:2134–2140.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia M, Huerta AJG, for the European LeukemiaNet. 2015. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia. 29:1084–1091.
   PubMed Web of Science ®Google Scholar
• Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, Ferrara F. 2002. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica. 87:485–489.
   PubMed Web of Science ®Google Scholar
• Li X, Geng Z, Wang S, Song X, Hu X, Wang Z. 2013. Functional evaluation of Asp76, 84, 102 and 150 in human arsenic (III) methyltransferase (hAS3MT) interacting with S-adenosylmethionine. FEBS Lett. 587:2232–2240.
   PubMed Web of Science ®Google Scholar
• Li J, Packianathan C, Rossman TG, Rosen BP. 2017a. Nonsynonymous polymorphisms in the human AS3MT arsenic methylation gene: implications for arsenic toxicity. Chem Res Toxicol. 30:1481–1491.
   PubMed Web of Science ®Google Scholar
• Li K, Wang F, Cao WB, Lv XX, Hua F, Cui B, Yu JJ, Zhang XW, Shang S, Liu SS, et al. 2017b. Trib3 promotes apl progression through stabilization of the oncoprotein PML/RARa and inhibition of p53-mediated senescence. Cancer Cell. 31:697–710.
   PubMed Web of Science ®Google Scholar
• Liu WS, Wang XY, Lu J, Zhang YM, Ye XM, Li JM, Zhao QL, Wu ZQ, Zhou J, Hai X, et al. 2020. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As2O3. Arch Toxicol. 94:1203–1213.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E. 2013. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 369:111–121.
   PubMed Web of Science ®Google Scholar
• Lu J, Hu S, Wang W, Li J, Dong Z, Zhou J, Hai X. 2018. AS3MT polymorphisms, arsenic metabolism, and the hematological and biochemical values in APL patients treated with arsenic trioxide. Toxicol Sci. 166:219–227.
   PubMed Web of Science ®Google Scholar
• Lu J, Yu K, Fan S, Liu W, Dong Z, Li J, Wang X, Hai X, Zhou J. 2019. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide. Toxicol Appl Pharmacol. 379:114687.
   PubMed Web of Science ®Google Scholar
• Maimaitiyiming Y, Shao YM, Chen WZ, Jiang Y, Bu N, Ma LY, Wang QQ, Lu XY, Naranmandura H. 2019. Irreversibility of arsenic trioxide induced PML/RARα fusion protein solubility changes. Metallomics. 11:2089–2096.
   PubMed Web of Science ®Google Scholar
• Maimaitiyiming Y, Wang C, Xu S, Islam K, Chen YJ, Yang C, Wang QQ, Naranmandura H. 2018. Role of arsenic (+ 3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation. Metallomics. 10:828–837.
   PubMed Web of Science ®Google Scholar
• Marty M, Ganem G, Fischer J, Flandrin G, Berger R, Schaison G, Boiron M. 1984. Leucémie aiguë promyélocytaire: étude rétrospective de 119 malades traités par daunorubicine. Nouvelle Revue Française D'hématologie. 26:371–378.
   PubMedGoogle Scholar
• Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, Shaji RV, Srivastava VM, Srivastava A, Chandy M. 2006. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 107:2627–2632.
   PubMed Web of Science ®Google Scholar
• Michieli M, Damiani D, Ermacora A, Geromin A, Michelutti A, Masolini P, Baccarani M. 2000. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol. 108:703–709.
   PubMed Web of Science ®Google Scholar
• Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. 2002. Mechanisms of action of arsenic trioxide. Cancer Res. 62:3893–3903.
   PubMed Web of Science ®Google Scholar
• Mishra D, Flora SJS. 2008. Differential oxidative stress and DNA damage in rat brain regions and blood following chronic arsenic exposure. Toxicol Ind Health. 24:247–256.
   PubMed Web of Science ®Google Scholar
• Mozier NM, McConnell KP, Hoffman JL. 1988. S-adenosyl-L-methionine:thioether S-methyltransferase, a new enzyme in sulfur and selenium metabolism. J Biol Chem. 263:4527–4531.
   PubMed Web of Science ®Google Scholar
• Naranmandura H, Suzuki N, Suzuki KT. 2006. Trivalent arsenicals are bound to proteins during reductive methylation. Chem Res Toxicol. 19:1010–1018.
   PubMed Web of Science ®Google Scholar
• Naranmandura H, Xu S, Koike S, Pan LQ, Chen B, Wang YW, Rehman K, Wu B, Chen Z, Suzuki N. 2012. The endoplasmic reticulum is a target organelle for trivalent dimethylarsinic acid (DMAIII)-induced cytotoxicity. Toxicol Appl Pharmacol. 260:241–249.
   PubMed Web of Science ®Google Scholar
• Naranmandura H, Xu S, Sawata T, Hao WH, Liu H, Bu N, Ogra Y, Lou YJ, Suzuki N. 2011. Mitochondria are the main target organelle for trivalent monomethylarsonous acid (MMAIII)-induced cytotoxicity. Chem Res Toxicol. 24:1094–1103.
   PubMed Web of Science ®Google Scholar
• Nesnow S, Roop BC, Lambert G, Kadiiska M, Mason RP, Cullen WR, Mass MJ. 2002. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol. 15:1627–1634.
   PubMed Web of Science ®Google Scholar
• Niwa-Kawakita M, Ferhi O, Soilihi H, Le Bras M, Lallemand-Breitenbach V, de Thé H. 2017. PML is a ROS sensor activating p53 upon oxidative stress. J Exp Med. 214:3197–3206.
   PubMed Web of Science ®Google Scholar
• Niwa-Kawakita M, Wu HC, de Thé H, Lallemand-Breitenbach V. 2018. PML nuclear bodies, membrane-less domains acting as ROS sensors? Semin Cell Dev Biol. 80:29–34.
   PubMed Web of Science ®Google Scholar
• Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Wiernik PH. 1994. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 8:968–973.
   PubMed Web of Science ®Google Scholar
• Panieri E, Santoro MM. 2016. Ros homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 7:e2253.
   PubMed Web of Science ®Google Scholar
• Pelicano H, Carney D, Huang P. 2004. Ros stress in cancer cells and therapeutic implications. Drug Resist Updat. 7:97–110.
   PubMed Web of Science ®Google Scholar
• Powell BL. 2011. Arsenic trioxide in acute promyelocytic leukemia: potion not poison. Expert Rev Anticancer Ther. 11:1317–1319.
   PubMed Web of Science ®Google Scholar
• Prasad S, Gupta SC, Tyagi AK. 2017. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer Lett. 387:95–105.
   PubMed Web of Science ®Google Scholar
• Qin J, Rosen BP, Zhang Y, Wang G, Franke S, Rensing C. 2006. Arsenic detoxification and evolution of trimethylarsine gas by a microbial arsenite S-adenosylmethionine methyltransferase. PNAS. 103:2075–2080.
   PubMed Web of Science ®Google Scholar
• Rehman K, Fu YJ, Zhang YF, Wang QQ, Wu B, Wu Y, Zhou XY, Sun WH, Sun TF, Naranmandura H. 2014. Trivalent methylated arsenic metabolites induce apoptosis in human myeloid leukemic HL-60 cells through generation of reactive oxygen species. Metallomics. 6:1502–1512.
   PubMed Web of Science ®Google Scholar
• Rehman K, Naranmandura H. 2012. Arsenic metabolism and thioarsenicals. Metallomics. 4:881–892.
   PubMed Web of Science ®Google Scholar
• Ren X, Aleshin M, Jo WJ, Dills R, Kalman DA, Vulpe CD, Smith MT, Zhang L. 2011. Involvement of N-6 adenine-specific DNA methyltransferase 1 (N6AMT1) in arsenic biomethylation and its role in arsenic-induced toxicity. Environ Health Perspect. 119:771–777.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. 1990. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 75:2112–2117.
   PubMed Web of Science ®Google Scholar
• Sahin U, Ferhi O, Jeanne M, Benhenda S, Berthier C, Jollivet F, Niwa-Kawakita M, Faklaris O, Setterblad N, de Thé H, et al. 2014. Oxidative stress-induced assembly of pml nuclear bodies controls sumoylation of partner proteins. J Cell Biol. 204:931–945.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P. 2014. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 123 :2777–2782.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H. 2009. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 113:1875–1891.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM. 2010. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 115:5137–5146.
   PubMed Web of Science ®Google Scholar
• Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. 2007. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. Embo J. 26:1749–1760.
   PubMed Web of Science ®Google Scholar
• Shen S, Li XF, Cullen WR, Weinfeld M, Le XC. 2013. Arsenic binding to proteins. Chem Rev. 113:7769–7792.
   PubMed Web of Science ®Google Scholar
• Song X, Geng Z, Li X, Zhao Q, Hu X, Zhang X, Wang Z. 2011. Functional and structural evaluation of cysteine residues in the human arsenic (+3 oxidation state) methyltransferase (hAS3MT). Biochimie. 93:369–375.
   PubMed Web of Science ®Google Scholar
• Su CT, Hsieh RL, Chung CJ, Huang PT, Lin YC, Ao PL, Shiue HS, Chen WJ, Huang SR, Lin MI. 2019. Plasma selenium influences arsenic methylation capacity and developmental delays in preschool children in Taiwan. Environ Res. 171:52–59.
   PubMed Web of Science ®Google Scholar
• Sumi D, Himeno S. 2012. Role of arsenic (+3 oxidation state) methyltransferase in arsenic metabolism and toxicity. Biol Pharm Bull. 35:1870–1875.
   PubMed Web of Science ®Google Scholar
• Sun HD, Ma L, Hu XC. 1991. The clinical report of 16 long-term survivors of acute promyelocytic leukemia treated with Ai-Ling 1 and traditional Chinese medicine. Inform Trad Chin Med. 6:39–41.
   Google Scholar
• Testa U, Lo-Coco F. 2015. Targeting of leukemia-initiating cells in acute promyelocytic leukemia. Stem Cell Investig. 2:8.
   PubMedGoogle Scholar
• Thomas DJ, Li J, Waters SB, Xing W, Adair BM, Drobna Z, Devesa V, Styblo M. 2007. Arsenic (+ 3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med (Maywood). 232:13.
   Google Scholar
• Wang S, Li X, Song X, Geng Z, Hu X, Wang Z. 2012. Rapid equilibrium kinetic analysis of arsenite methylation catalyzed by recombinant human arsenic (+ 3 oxidation state) methyltransferase (hAS3MT). J Biol Chem. 287:38790–38799.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou J, Lu X, Gong Z, Le XC. 2004. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol. 17:95–103.
   PubMed Web of Science ®Google Scholar
• Wang QQ, Zhou XY, Zhang YF, Bu N, Zhou J, Cao FL, Naranmandura H. 2015. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation. Oncotarget. 6:25646–25659.
   PubMedGoogle Scholar
• Waters SB, Lin S, Styblo M, Thomas DJ. 2003. A novel S-adenosylmethionine-dependent methyltransferase from rat liver cytosol catalyzes the formation of methylated arsenicals. In: Chappell WR, Abernathy CO, Calderon RL, Thomas DJ, editors. Arsenic Exposure Health Effects V. Amsterdam (The Netherlands): Elsevier; p. 255–266.
   Google Scholar
• Wildfang E, Radabaugh TR, Aposhian HV. 2001. Enzymatic methylation of arsenic compounds. IX. Liver arsenite methyltransferase and arsenate reductase activities in primates. Toxicology. 168:213–221.
   PubMed Web of Science ®Google Scholar
• Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M. 2010. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs. 28:670–676.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang H, Li H, Hu X, Zhang Y, Guan X, Toy PH, Sun H. 2019. S-Dimethylarsino-glutathione (darinaparsin®) targets histone H3.3, leading to TRAIL-induced apoptosis in leukemia cells. Chem Commun (Camb). 55:13120–13123.
   PubMed Web of Science ®Google Scholar
• Yokohira M, Arnold LL, Pennington KL, Suzuki S, Kakiuchi-Kiyota S, Herbin-Davis K, Thomas DJ, Cohen SM. 2011. Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (+3 oxidation state) methyltransferase knockout mice. Toxicol Sci. 121:257–266.
   PubMed Web of Science ®Google Scholar
• Zakharyan R, Wu Y, Bogdan GM, Aposhian HV. 1995. Enzymic methylation of arsenic compounds: assay, partial purification, and properties of arsenite methyltransferase and monomethylarsonic acid methyltransferase of rabbit liver. Chem Res Toxicol. 8:1029–1038.
   PubMed Web of Science ®Google Scholar
• Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, et al. 2010. Arsenic trioxide controls the fate of the pml-rara oncoprotein by directly binding pml. Science. 328:240–243.
   PubMed Web of Science ®Google Scholar
• Zhao J, Liang JW, Xue HL, Shen SH, Chen J, Tang YJ, Yu LS, Liang HH, Gu LJ, Tang JY. 2019. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia. 33:1387–1399.
   PubMed Web of Science ®Google Scholar
• Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M, Quignon F, Rochette-Egly C, de The H. 1999. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RARα) and oncogenic RARα fusion proteins. Proc Natl Acad Sci. 96:14807–14812.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Hu J, Lo-Coco F, Jin J. 2019. The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 134:597–605.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Liu YR, Jia JS, Qin YZ, Zhao XS, Lai YY. 2018a. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood. 131:2987–2989.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL. 2018b. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. The Lancet. 19:871–879.
   PubMed Web of Science ®Google Scholar
• Zwolak I. 2020. The role of selenium in arsenic and cadmium toxicity: an updated review of scientific literature. Biol Trace Elem Res. 193:44–63.
   PubMed Web of Science ®Google Scholar